Adverse remodelling following an initial insult is the hallmark of heart failure (HF) development and progression. It is manifested as changes in size, shape, and function of the myocardium. While cardiac remodelling may be compensatory in the short term, further neurohumoral activation and haemodynamic overload drive this deleterious process that is associated with impaired prognosis. However, in some patients, the changes may be reversed. Left ventricular reverse remodelling (LVRR) is characterized as a decrease in chamber volume and normalization of shape associated with improvement in both systolic and diastolic function. LVRR might occur spontaneously or more often in response to therapeutic interventions that either remove the initial stressor or alleviate some of the mechanisms that contribute to further deterioration of the failing heart. Although the process of LVRR in patients with new-onset HF may take up to 2 years after initiating treatment, there is a significant portion of patients who do not improve despite optimal therapy, which has serious clinical implications when considering treatment escalation towards more aggressive options. On the contrary, in patients that achieve delayed improvement in cardiac function and architecture, waiting might avoid untimely implantable cardioverter-defibrillator implantation. Therefore, prognostication of successful LVRR based on clinical, imaging, and biomarker predictors is of utmost importance. LVRR has a positive impact on prognosis. However, reverse remodelled hearts continue to have abnormal features. In fact, most of the molecular, cellular, interstitial, and genome expression abnormalities remain and a susceptibility to dysfunction redevelopment under biomechanical stress persists in most patients. Hence, a distinction should be made between reverse remodelling and true myocardial recovery. In this comprehensive review, current evidence on LVRR, its predictors, and implications on prognostication, with a specific focus on HF patients with non-ischaemic cardiomyopathy, as well as on novel drugs, is presented.

Department of Cardiology 2nd Faculty of Medicine Charles University and University Hospital Motol 5 Úvalu 84 1 Prague 15006 Czech Republic

See more in PubMed

Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling—concepts and clinical implications: a consensus paper from an International Forum on Cardiac Remodeling. J Am Coll Cardiol. 2000; 35: 569–582. PubMed

Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction: experimental observations and clinical implications. Circulation. 1990; 81: 1161–1172. PubMed

Florea VG, Mareyev VY, Samko AN, Orlova IA, Coats AJS, Belenkov YN. Left ventricular remodelling: common process in patients with different primary myocardial disorders. Int J Cardiol. 1999; 68: 281–287. PubMed

Kass DA, Baughman KL, Pak PH, Cho PW, Levin HR, Gardner TJ, Halperin HR, Tsitlik JE, Acker MA. Reverse remodeling from cardiomyoplasty in human heart failure: external constraint versus active assist. Circulation. 1995; 91: 2314–2318. PubMed

Merlo M, Pyxaras SA, Pinamonti B, Barbati G, Di LA, Sinagra G. Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment. J Am Coll Cardiol. 2011; 57: 1468–1476. PubMed

Chung ES, Leon AR, Tavazzi L, Sun JP, Nihoyannopoulos P, Merlino J, Abraham WT, Ghio S, Leclercq C, Bax JJ, Yu CM, Gorcsan J, Sutton MSJ, De SJ, Murillo J. Results of the predictors of response to CRT (PROSPECT) trial. Circulation. 2008; 117: 2608–2616. PubMed

Wilcox JE, Fonarow GC, Yancy CW, Albert NM, Curtis AB, Heywood JT, Inge PJ, McBride ML, Mehra MR, O'Connor CM, Reynolds D, Walsh MN, Gheorghiade M. Factors associated with improvement in ejection fraction in clinical practice among patients with heart failure: findings from IMPROVE HF. Am Heart J. 2012; 163: 163–56.e2. PubMed

Brenyo A, Barsheshet A, Kutyifa V, Ruwald AC, Rao M, Zareba W, Pouleur AC, Knappe D, Solomon SD, McNitt S, Huang DT, Moss AJ, Goldenberg I. Predictors of spontaneous reverse remodeling in mild heart failure patients with left ventricular dysfunction. Circ Hear Fail. 2014; 7: 565–572. PubMed

Masci PG, Schuurman R, Andrea B, Ripoli A, Coceani M, Chiappino S, Todiere G, Srebot V, Passino C, Aquaro GD, Emdin M, Lombardi M. Myocardial fibrosis as a key determinant of left ventricular remodeling in idiopathic dilated cardiomyopathy: a contrast‐enhanced cardiovascular magnetic study. Circ Cardiovasc Imaging. 2013; 6: 790–799. PubMed

Kubanek M, Sramko M, Maluskova J, Kautznerova D, Weichet J, Lupinek P, Vrbska J, Malek I, Kautzner J. Novel predictors of left ventricular reverse remodeling in individuals with recent‐onset dilated cardiomyopathy. J Am Coll Cardiol. 2013; 61: 54–63. PubMed

Kim GH, Uriel N, Burkhoff D. Reverse remodelling and myocardial recovery in heart failure. Nat Rev Cardiol. 2018; 15: 83–96. PubMed

Barbone A, Holmes JW, Heerdt PM, The' AH, Naka Y, Joshi N, Daines M, Marks AR, Oz MC, Burkhoff D. Comparison of right and left ventricular responses to left ventricular assist device support in patients with severe heart failure. Circulation. 2001; 104: 670–675. PubMed

Klotz S, Barbone A, Reiken S, Holmes JW, Naka Y, Oz MC, Marks AR, Burkhoff D. Left ventricular assist device support normalizes left and right ventricular beta‐adrenergic pathway properties. J Am Coll Cardiol. 2005; 45: 668–676. PubMed

Margulies KB, Matiwala S, Cornejo C, Olsen H, Craven WA, Bednarik D. Mixed messages: transcription patterns in failing and recovering human myocardium. Circ Res. 2005; 96: 592–599. PubMed

Binkley PF, Lesinski A, Ferguson JP, Hatton PS, Yamokoski L, Hardikar S, Cooke GE, Leier CV. Recovery of normal ventricular function in patients with dilated cardiomyopathy: predictors of an increasingly prevalent clinical event. Am Heart J. 2008; 155: 69–74. PubMed

Yang KC, Yamada KA, Patel AY, Topkara VK, George I, Cheema FH, Ewald GA, Mann DL, Nerbonne JM. Deep RNA sequencing reveals dynamic regulation of myocardial noncoding RNAs in failing human heart and remodeling with mechanical circulatory support. Circulation. 2014; 129: 1009–1021. PubMed PMC

Mann DL, Barger PM, Burkhoff D. Myocardial recovery and the failing heart: myth, magic, or molecular target? J Am Coll Cardiol. 2012; 60: 2465–2472. PubMed PMC

Topkara VK, Garan AR, Fine B, Godier‐Furnémont AF, Breskin A, Cagliostro B, Yuzefpolskaya M, Takeda K, Takayama H, Mancini DM, Naka Y, Colombo PC. Myocardial recovery in patients receiving contemporary left ventricular assist devices. Circ Hear Fail. 2016; 9: 9. PubMed PMC

Hetzer R, Müller J, Weng Y, Wallukat G, Spiegelsberger S, Loebe M. Cardiac recovery in dilated cardiomyopathy by unloading with a left ventricular assist device. Ann Thorac Surg. 1999; 68: 742–749. PubMed

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González‐Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Authors/Task Force Members, Document Reviewers . ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution. Eur J Heart Fail 2016. 2016; 18: 891–975. PubMed

Saraon T, Katz SD. Reverse remodeling in systolic heart failure. Cardiol Rev. 2015; 23: 173–181. PubMed

Pieske B. Reverse remodeling in heart failure—fact or fiction? Eur Heart Journal, Suppl. 2004; 6: D66–D78.

Hellawell JL, Margulies KB. Myocardial reverse remodeling. Cardiovasc Ther. 2012; 30: 172–181. PubMed

Kramer DG, Trikalinos TA, Kent DM, Antonopoulos GV, Konstam MA, Udelson JE. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta‐analytic approach. J Am Coll Cardiol. 2010; 56: 392–406. PubMed PMC

Goldstein S, Kennedy HL, Hall C, Anderson JL, Gheorghiade M, Gottlieb S, Jessup M, Karlsberg RP, Friday G, Haskell L. Metoprolol CR/XL in patients with heart failure: a pilot study examining the tolerability, safety, and effect on left ventricular ejection fraction. Am Heart J. 1999; 138: 1158–1165. PubMed

Groenning BA, Nilsson JC, Sondergaard L, Fritz‐Hansen T, Larsson HBW, Hildebrandt PR. Antiremodeling effects on the left ventricle during beta‐blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol. 2000; 36: 2072–2080. PubMed

White M, Yusuf S, McKelvie RS, Pericak D, Young J, Latini R, Pogue J, Burns RJ, Probstfield J, Tsuyuki RT, Maggioni AP, Avezum AJ, Rouleau JL. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation. 2000; 101: 378–384. PubMed

Colucci WS, Kolias TJ, Adams KF, Armstrong WF, Ghali JK, Gottlieb SS, Greenberg B, Klibaner MI, Kukin ML, Sugg JE. Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular remodeling with Toprol‐XL (REVERT) trial. Circulation. 2007; 116: 49–56. PubMed

Palazzuoli A, Bruni F, Puccetti L, Pastorelli M, Angori P, Pasqui AL, Auteri A. Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure. Eur J Heart Fail. 2002; 4: 765–770. PubMed

Packer M, Colucci WS, Sackner‐Bernstein JD, Liang CS, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D, Cody RJ, Gregory JJ, Kantrowitz NE, LeJemtel TH, Young ST, Lukas MA, Shusterman NH. Double‐blind, placebo‐controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation. 1996; 94: 2793–2799. PubMed

Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N. Carvedilol produces dose‐related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation. 1996; 94: 2807–2816. PubMed

Léchât P, Escolano S, Golmard JL, Lardoux H, Witchitz S, Henneman JA, Maisch B, Hetzel M, Jaillon P, Boissel JP, Mallet A. Prognostic value of bisoprolol‐induced hemodynamic effects in heart failure during the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation. 1997; 96: 2197–2205. PubMed

Dubach P, Myers J, Bonetti P, Schertler T, Froelicher V, Wagner D, Scheidegger M, Stuber M, Luchinger R, Schwitter J, Hess O. Effects of bisoprolol fumarate on left ventricular size, function, and exercise capacity in patients with heart failure: analysis with magnetic resonance myocardial tagging. Am Heart J. 2002; 143: 676–683. PubMed

Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta‐adrenergic blockade. J Am Coll Cardiol. 1995; 25: 1154–1161. PubMed

Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP. Clinical effects of beta‐adrenergic blockade in chronic heart failure: a meta‐analysis of double‐blind, placebo‐controlled, randomized trials. Circulation. 1998; 98: 1184–1191. PubMed

Yusuf S. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. Ann Intern Med. 1991; 115: 67. PubMed

Greenberg B, Quinones MA, Koilpillai C, Limacher M, Shindler D, Benedict C, Shelton B. Effects of long‐term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction results of the SOLVD echocardiography substudy. Circulation. 1995; 91: 2573–2581. PubMed

Konstam MA, Rousseau MF, Kronenberg MW, Udelson JE, Melin J, Stewart D, Dolan N, Edens TR, Ahn S, Kinan D, Howe DM, Kilcoyne L, Metherall J, Benedict C, Yusuf S, Pouleur H. Effects of the angiotensin converting enzyme inhibitor enalapril on the long‐term progression of left ventricular dysfunction in patients with heart failure. Circulation. 1992; 86: 431–438. PubMed

Keren G, Pardes A, Eschar Y, Koifman B, Scherez J, Geleranter I, Laniado S. One‐year clinical and echocardiographic follow‐up of patients with congestive cardiomyopathy treated with captopril compared to placebo. Isr J Med Sci. 1994; 30: 90–98. PubMed

Khattar RS, Senior R, Soman P, Van Der Does R, Lahiri A. Regression of left ventricular remodeling in chronic heart failure: comparative and combined effects of captopril and carvedilol. Am Heart J. 2001; 142: 704–713. PubMed

Wong M, Staszewsky L, Latini R, Barlera S, Volpi A, Chiang YT, Benza RL, Gottlieb SO, Kleemann TD, Rosconi F, Vandervoort PM, Cohn JN. Valsartan benefits left ventricular structure and function in heart failure: Val‐HeFT echocardiographic study. J Am Coll Cardiol. 2002; 40: 970–975. PubMed

Matsumori A, Assessment of Response to Candesartan in Heart Failure in Japan (ARCH‐J) Study Investigators . Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. Eur J Heart Fail. 2003; 5: 669–677. PubMed

Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T, Matsui T, Kinoshita M. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol. 2001; 37: 1228–1233. PubMed

Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Brighetti G, Marino P, Zardini P. Long‐term, dose‐dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol. 2002; 40: 304–310. PubMed

Chan AKY, Sanderson JE, Wang T, Lam W, Yip G, Wang M, Lam YY, Zhang Y, Yeung L, Wu EB, Chan WWM, Wong JTH, So N, Yu CM. Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure. J Am Coll Cardiol. 2007; 50: 591–596. PubMed

Udelson JE, Feldman AM, Greenberg B, Pitt B, Mukherjee R, Solomon HA, Konstam MA. Randomized, double‐blind, multicenter, placebo‐controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild‐to‐moderate heart failure and left ventricular systolic dysfunction. Circ Hear Fail. 2010; 3: 347–353. PubMed

Li X, Qi Y, Li Y, Zhang S, Guo S, Chu S, Gao P, Zhu D, Wu Z, Lu L, Shen W, Jia N, Niu W. Impact of mineralocorticoid receptor antagonists on changes in cardiac structure and function of left ventricular dysfunction a meta‐analysis of randomized controlled trials. Circ Hear Fail. 2013; 6: 156–165. PubMed

McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM, DAPA‐HF Trial Committees and Investigators . Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019; 381: 1995–2008. PubMed

Martens P, Beliën H, Dupont M, Vandervoort P, Mullens W. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction. Cardiovasc Ther. 2018; 36: 36. PubMed

Januzzi JL, Prescott MF, Butler J, Felker GM, Maisel AS, McCague K, Camacho A, Pinã IL, Rocha RA, Shah AM, Williamson KM, Solomon SD. Association of change in n‐terminal pro‐b‐type natriuretic peptide following initiation of sacubitril‐valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA ‐ J Am Med Assoc. 2019; 322: 1085–1095. PubMed PMC

Moon MG, Hwang IC, Choi W, Cho GY, Yoon YE, Park JB, Lee SP, Kim HK, Kim YJ. Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction. ESC Hear Fail. 2021; 8: 2058–2069. PubMed PMC

Kang DH, Park SJ, Shin SH, Hong GR, Lee S, Kim MS, Yun SC, Song JM, Park SW, Kim JJ. Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation: PRIME study. Circulation. 2019; 139: 1354–1365. PubMed

Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta‐analysis of cardiovascular outcome trials. Lancet. 2019; 393: 31–39. PubMed

Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Böhm M, Choi D‐J, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner‐La Rocca H‐P, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F, EMPEROR‐Reduced Trial Investigators . Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020; 383: 1413–1424. PubMed

Singh JSS, Mordi IR, Vickneson K, Fathi A, Donnan PT, Mohan M, Choy AMJ, Gandy S, George J, Khan F, Pearson ER, Graeme Houston J, Struthers AD, Lang CC. Dapagliflozin versus placebo on left ventricular remodeling in patients with diabetes and heart failure: the Reform trial. Diabetes Care. 2020; 43: 1356–1359. PubMed PMC

Lee MMY, Brooksbank KJM, Wetherall K, Mangion K, Roditi G, Campbell RT, Berry C, Chong V, Coyle L, Docherty KF, Dreisbach JG, Labinjoh C, Lang NN, Lennie V, McConnachie A, Murphy CL, Petrie CJ, Petrie JR, Speirits IA, Sourbron S, Welsh P, Woodward R, Radjenovic A, Mark PB, McMurray JJV, Jhund PS, Petrie MC, Sattar N. Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR‐DM‐HF). Circulation. 2021; 143: 516–525. PubMed PMC

Aleksova A, Carriere C, Zecchin M, Barbati G, Vitrella G, Di LA, Sinagra G. New‐onset left bundle branch block independently predicts long‐term mortality in patients with idiopathic dilated cardiomyopathy: data from the Trieste Heart Muscle Disease Registry. Europace. 2014; 16: 1450–1459. PubMed

Witt CM, Wu G, Yang D, Hodge DO, Roger VL, Cha YM. Outcomes with left bundle branch block and mildly to moderately reduced left ventricular function. JACC Hear Fail. 2016; 4: 897–903. PubMed

Lund LH, Jurga J, Edner M, Benson L, Dahlström U, Linde C, Alehagen U. Prevalence, correlates, and prognostic significance of QRS prolongation in heart failure with reduced and preserved ejection fraction. Eur Heart J. 2013; 34: 529–539. PubMed

Sze E, Samad Z, Dunning A, Campbell KB, Loring Z, Atwater BD, Chiswell K, Kisslo JA, Velazquez EJ, Daubert JP. Impaired recovery of left ventricular function in patients with cardiomyopathy and left bundle branch block. J Am Coll Cardiol. 2018; 71: 306–317. PubMed PMC

Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De MT, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM. Cardiac‐resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004; 350: 2140–2150. PubMed

Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NAM, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W. Cardiac‐resynchronization therapy for the prevention of heart‐failure events. N Engl J Med. 2009; 361: 1329–1338. PubMed

Duncan A, Wait D, Gibson D, Daubert JC. Left ventricular remodelling and haemodynamic effects of multisite biventricular pacing in patients with left ventricular systolic dysfunction and activation disturbances in sinus rhythm: sub‐study of the MUSTIC (Multisite Stimulation in Cardiomyopathies) trial. Eur Heart J. 2003; 24: 430–441. PubMed

St. John Sutton M, Ghio S, Plappert T, Tavazzi L, Scelsi L, Daubert C, Abraham WT, Gold MR, Hassager C, Herre JM, Linde C. Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association class I/II heart failure. Circulation. 2009; 120: 1858–1865. PubMed

Sutton MSJ, Keane MG. Reverse remodelling in heart failure with cardiac resynchronisation therapy. Heart. 2007; 93: 167–171. PubMed PMC

St. John Sutton M, Plappert T, Abraham WT, Smith AL, DeLurgio DB, Leon AR, Loh E, Kocovic DZ, Fisher WG, Ellestad M, Messenger J, Kruger K, Hilpisch KE, Hill MRS. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation. 2003; 107: 1985–1990. PubMed

Verhaert D, Grimm RA, Puntawangkoon C, Wolski K, De S , Wilkoff BL, Starling RC, Tang WHW, Thomas JD, Popović ZB. Long‐term reverse remodeling with cardiac resynchronization therapy. Results of extended echocardiographic follow‐up. J Am Coll Cardiol. 2010; 55: 1788–1795. PubMed

Linde C, Gold MR, Abraham WT, St John Sutton M, Ghio S, Cerkvenik J, Daubert C. Long‐term impact of cardiac resynchronization therapy in mild heart failure: 5‐year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. Eur Heart J. 2013; 34: 2592–2599. PubMed

Rossi A, Dini FL, Faggiano P, Agricola E, Cicoira M, Frattini S, Simioniuc A, Gullace M, Ghio S, Enriquez‐Sarano M, Temporelli PL. Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non‐ischaemic dilated cardiomyopathy. Heart. 2011; 97: 1675–1680. PubMed

Grayburn PA, Sannino A, Packer M. Proportionate and disproportionate functional mitral regurgitation: a new conceptual framework that reconciles the results of the MITRA‐FR and COAPT trials. JACC Cardiovasc Imaging. 2019; 12: 353–362. PubMed

De BM, Lapenna E, Verzini A, La CG, Grimaldi A, Torracca L, Maisano F, Alfieri O. Recurrence of mitral regurgitation parallels the absence of left ventricular reverse remodeling after mitral repair in advanced dilated cardiomyopathy. Ann Thorac Surg. 2008; 85: 932–939. PubMed

Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, Whisenant B, Grayburn PA, Rinaldi M, Kapadia SR, Rajagopal V, Sarembock IJ, Brieke A, Marx SO, Cohen DJ, Weissman NJ, Mack MJ. Transcatheter mitral‐valve repair in patients with heart failure. N Engl J Med. 2018; 379: 2307–2318. PubMed

Obadia J‐F, Messika‐Zeitoun D, Leurent G, Iung B, Bonnet G, Piriou N, Lefèvre T, Piot C, Rouleau F, Carrié D, Nejjari M, Ohlmann P, Leclercq F, Saint EC, Teiger E, Leroux L, Karam N, Michel N, Gilard M, Donal E, Trochu J‐N, Cormier B, Armoiry X, Boutitie F, Maucort‐Boulch D, Barnel C, Samson G, Guerin P, Vahanian A, Mewton N. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med. 2018; 379: 2297–2306. PubMed

Gripari P, Tamborini G, Bottari V, Maffessanti F, Carminati MC, Muratori M, Vignati C, Bartorelli AL, Alamanni F, Pepi M. Three‐dimensional transthoracic echocardiography in the comprehensive evaluation of right and left heart chamber remodeling following percutaneous mitral valve repair. J Am Soc Echocardiogr. 2016; 29: 946–954. PubMed

Papadopoulos K, Ikonomidis I, Chrissoheris M, Chalapas A, Kourkoveli P, Parissis J, Spargias K. MitraClip and left ventricular reverse remodelling: a strain imaging study. ESC Hear Fail. 2020; 7: 1409–1418. PubMed PMC

Megaly M, Khalil C, Abraham B, Saad M, Tawadros M, Stanberry L, Kalra A, Goldsmith SR, Bart B, Bae R, Brilakis ES, Gössl M, Sorajja P. Impact of transcatheter mitral valve repair on left ventricular remodeling in secondary mitral regurgitation: a meta‐analysis. Struct Hear. 2018; 2: 541–547.

Adamo M, Godino C, Giannini C, Scotti A, Liga R, Curello S, Fiorina C, Chiari E, Chizzola G, Abbenante A, Visco E, Branca L, Fiorelli F, Agricola E, Stella S, Lombardi C, Colombo A, Petronio AS, Metra M, Ettori F. Left ventricular reverse remodelling predicts long‐term outcomes in patients with functional mitral regurgitation undergoing MitraClip therapy: results from a multicentre registry. Eur J Heart Fail. 2019; 21: 196–204. PubMed

Masè M, Merlo M, Vitrella G, Stolfo D, Sinagra G. Left ventricular reverse remodeling prediction in non‐ischemic cardiomyopathy: present and perspectives. Expert Rev Cardiovasc Ther. 2018; 16: 771–773. PubMed

Cicoira M, Zanolla L, Latina L, Rossi A, Golia G, Brighetti G, Zardini P. Frequency, prognosis and predictors of improvement of systolic left ventricular function in patients with ‘classical’ clinical diagnosis of idiopathic dilated cardiomyopathy. Eur J Heart Fail. 2001; 3: 323–330. PubMed

Choi JO, Kim EY, Lee GY, Lee SC, Park SW, Kim DK, Oh JK, Jeon ES. Predictors of left ventricular reverse remodeling and subsequent outcome in nonischemic dilated cardiomyopathy. Circ J. 2013; 77: 462–469. PubMed

D'Auria F, Polito MV, Vitulano G, Ciccarelli M, De RR, Gigantino A, Piscione F, Galasso G. Predictors of left ventricular reverse remodeling in patients with chronic heart failure. J Cardiovasc Med. 2018; 19: 465–469. PubMed

Merlo M, Cannatà A, Gobbo M, Stolfo D, Elliott PM, Sinagra G. Evolving concepts in dilated cardiomyopathy. Eur J Heart Fail. 2018; 20: 228–239. PubMed

Aimo A, Vergaro G, Castiglione V, Barison A, Pasanisi E, Petersen C, Chubuchny V, Giannoni A, Poletti R, Maffei S, Januzzi JL, Passino C, Emdin M. Effect of sex on reverse remodeling in chronic systolic heart failure. JACC Hear Fail. 2017; 5: 735–742. PubMed

Dal Ferro M, Stolfo D, Altinier A, Gigli M, Perrieri M, Ramani F, Barbati G, Pivetta A, Brun F, Monserrat L, Giacca M, Mestroni L, Merlo M, Sinagra G. Association between mutation status and left ventricular reverse remodelling in dilated cardiomyopathy. Heart. 2017; 103: 1704–1710. PubMed

Brenyo A, Barsheshet A, Kutyifa V, Ruwald A‐C, Rao M, Zareba W, Pouleur A‐C, Knappe D, Solomon SD, McNitt S, Huang DT, Moss AJ, Goldenberg I. Predictors of spontaneous reverse remodeling in mild heart failure patients with left ventricular dysfunction. Circ Heart Fail. 2014; 7: 565–572. PubMed

Lupón J, Gaggin HK, De AM, Domingo M, Galán A, Zamora E, Vila J, Peñafiel J, Urrutia A, Ferrer E, Vallejo N, Januzzi JL, Bayes‐Genis A. Biomarker‐assist score for reverse remodeling prediction in heart failure: the ST2‐R2 score. Int J Cardiol. 2015; 184: 337–343. PubMed

Amorim S, Campelo M, Martins E, Moura B, Sousa A, Pinho T, Silva‐Cardoso J, Maciel MJ. Prevalence, predictors and prognosis of ventricular reverse remodeling in idiopathic dilated cardiomyopathy. Rev Port Cardiol. 2016; 35: 253–260. PubMed

Marsan NA, Breithardt OA, Delgado V, Bertini M, Tops LF. Predicting response to CRT. The value of two‐ and three‐dimensional echocardiography. Europace. 2008; 10: iii73–iii79. PubMed

Lim P, Donal E, Lafitte S, Derumeaux G, Habib G, Rant P, Thivolet S, Lellouche N, Grimm RA, Gueret P. Multicentre study using strain delay index for predicting response to cardiac resynchronization therapy (MUSIC study). Eur J Heart Fail. 2011; 13: 984–991. PubMed

Barison A, Aimo A, Ortalda A, Todiere G, Grigoratos C, Passino C, Camici PG, Aquaro GD, Emdin M. Late gadolinium enhancement as a predictor of functional recovery, need for defibrillator implantation and prognosis in non‐ischemic dilated cardiomyopathy. Int J Cardiol. 2018; 250: 195–200. PubMed

Chen Z, Sohal M, Sammut E, Child N, Jackson T, Claridge S, Cooklin M, O'Neill M, Wright M, Gill J, Chiribiri A, Schaeffter T, Carr‐White G, Razavi R, Rinaldi CA. Focal but not diffuse myocardial fibrosis burden quantification using cardiac magnetic resonance imaging predicts left ventricular reverse modeling following cardiac resynchronization therapy. J Cardiovasc Electrophysiol. 2016; 27: 203–209. PubMed

Januzzi JL, Rehman SU, Mohammed AA, Bhardwaj A, Barajas L, Barajas J, Kim HN, Baggish AL, Weiner RB, Chen‐Tournoux A, Marshall JE, Moore SA, Carlson WD, Lewis GD, Shin J, Sullivan D, Parks K, Wang TJ, Gregory SA, Uthamalingam S, Semigran MJ. Use of amino‐terminal ProB‐type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol. 2011; 58: 1881–1889. PubMed

Daubert MA, Adams K, Yow E, Barnhart HX, Douglas PS, Rimmer S, Norris C, Cooper L, Leifer E, Desvigne‐Nickens P, Anstrom K, Fiuzat M, Ezekowitz J, Mark DB, O'Connor CM, Januzzi J, Felker GM. NT‐proBNP goal achievement is associated with significant reverse remodeling and improved clinical outcomes in HFrEF. JACC Hear Fail. 2019; 7: 158–168. PubMed

Lupón J, Sanders‐Van Wijk S, Januzzi JL, De Antonio M, Gaggin HK, Pfisterer M, Galán A, Shah R, Brunner‐La Rocca HP, Bayes‐Genis A. Prediction of survival and magnitude of reverse remodeling using the ST2‐R2 score in heart failure: a multicenter study. Int J Cardiol. 2016; 204: 242–247. PubMed

Lupón J, Gavidia‐Bovadilla G, Ferrer E, de Antonio M, Perera‐Lluna A, López‐Ayerbe J, Domingo M, Núñez J, Zamora E, Moliner P, Díaz‐Ruata P, Santesmases J, Bayés‐Genís A. Dynamic trajectories of left ventricular ejection fraction in heart failure. J Am Coll Cardiol. 2018; 72: 591–601. PubMed

Aleksova A, Sabbadini G, Merlo M, Pinamonti B, Barbati G, Zecchin M, Bussani R, Silvestri F, Iorio AM, Stolfo D, Dal Ferro M, Dragos AM, Meringolo G, Pyxaras S, Lo GF, Perkan A, di LA, Sinagra G. Natural history of dilated cardiomyopathy: from asymptomatic left ventricular dysfunction to heart failure—a subgroup analysis from the Trieste Cardiomyopathy Registry. J Cardiovasc Med. 2009; 10: 699–705. PubMed

Florea VG, Rector TS, Anand IS, Cohn JN. Heart failure with improved ejection fraction: clinical characteristics, correlates of recovery, and survival. Circ Hear Fail. 2016; 9: 9. PubMed

Basuray A, French B, Ky B, Vorovich E, Olt C, Sweitzer NK, Cappola TP, Fang JC. Heart failure with recovered ejection fraction. Circulation. 2014; 129: 2380–2387. PubMed PMC

Wilcox JE, Fang JC, Margulies KB, Mann DL. Heart failure with recovered left ventricular ejection fraction: JACC Scientific Expert Panel. J Am Coll Cardiol. 2020; 76: 719–734. PubMed

Duncker D, König T, Hohmann S, Bauersachs J, Veltmann C. Avoiding untimely implantable cardioverter/defibrillator implantation by intensified heart failure therapy optimization supported by the wearable cardioverter/defibrillator—the PROLONG study. J Am Heart Assoc. 2017; 6: 1–9. PubMed PMC

DeFilippis EM, Butler J, Vaduganathan M. Waiting period before implantable cardioverter‐defibrillator implantation in newly diagnosed heart failure with reduced ejection fraction: a window of opportunity. Circ Hear Fail. 2017; 10: 1–5. PubMed PMC

Halliday BP, Wassall R, Lota AS, Khalique Z, Gregson J, Newsome S, Jackson R, Rahneva T, Wage R, Smith G, Venneri L, Tayal U, Auger D, Midwinter W, Whiffin N, Rajani R, Dungu JN, Pantazis A, Cook SA, Ware JS, Baksi AJ, Pennell DJ, Rosen SD, Cowie MR, Cleland JGF, Prasad SK. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED‐HF): an open‐label, pilot, randomised trial. Lancet. 2019; 393: 61–73. PubMed PMC

Cay S, Ozeke O, Ozcan F, Aras D, Topaloglu S. Mid‐term clinical and echocardiographic evaluation of super responders with and without pacing: the preliminary results of a prospective, randomized, single‐centre study. Europace. 2016; 18: 842–850. PubMed

Pfeffer MA, Pfeffer JM, Fishbein MC, Fletcher PJ, Spadaro J, Kloner RA, Braunwald E. Myocardial infarct size and ventricular function in rats. Circ Res. 1979; 44: 503–512. PubMed

Patten RD, Aronovitz MJ, Deras‐Mejia L, Pandian NG, Hanak GG, Smith JJ, Mendelsohn ME, Konstam MA. Ventricular remodeling in a mouse model of myocardial infarction. Am J Physiol. 1998; 274: H1812–H1820. PubMed

Michael LH, Entman ML, Hartley CJ, Youker KA, Zhu J, Hall SR, Hawkins HK, Berens K, Ballantyne CM. Myocardial ischemia and reperfusion: a murine model. Am J Physiol. 1995; 269: H2147–H2154. PubMed

Hutchinson KR, Guggilam A, Cismowski MJ, Galantowicz ML, West TA, Stewart JA Jr, Zhang X, Lord KC, Lucchesi PA. Temporal pattern of left ventricular structural and functional remodeling following reversal of volume overload heart failure. J Appl Physiol (1985). 2011; 111: 1778–1788. PubMed PMC

Kala P, Miklovic M, Jichova S, Skaroupkova P, Vanourkova Z, Maxova H, Gawrys O, Kompanowska‐Jezierska E, Sadowski J, Imig JD, Falck JR, Veselka J, Cervenka L, Aiglova R, Vicha M, Gloger V, Taborsky M. Effects of epoxyeicosatrienoic acid‐enhancing therapy on the course of congestive heart failure in angiotensin II‐dependent rat hypertension: from mRNA analysis towards functional in vivo evaluation. Biomedicine. 2021; 9: 1053. PubMed PMC

Chu G, Haghighi K, Kranias EG. From mouse to man: understanding heart failure through genetically altered mouse models. J Card Fail. 2002; 8: S432–S449. PubMed

Robert J. Long‐term and short‐term models for studying anthracycline cardiotoxicity and protectors. Cardiovasc Toxicol. 2007; 7: 135–139. PubMed

Kala P, Bartuskova H, Pitha J, Vanourkova Z, Kikerlova S, Jichova S, Melenovsky V, Hoskova L, Veselka J, Kompanowska‐Jezierska E, Sadowski J, Gawrys O, Maxova H, Cervenka L. Deleterious effects of hyperactivity of the renin‐angiotensin system and hypertension on the course of chemotherapy‐induced heart failure after doxorubicin administration: a study in Ren‐2 transgenic rat. Int J Mol Sci. 2020; 21: 9337. PubMed PMC

Teerlink JR, Pfeffer JM, Pfeffer MA. Progressive ventricular remodeling in response to diffuse isoproterenol‐induced myocardial necrosis in rats. Circ Res. 1994; 75: 105–113. PubMed

Prabhu SD, Freeman GL. Effect of tachycardia heart failure on the restitution of left ventricular function in closed‐chest dogs. Circulation. 1995; 91: 176–185. PubMed

Akhter SA, D'Souza KM, Malhotra R, Staron ML, Valeroso TB, Fedson SE, Anderson AS, Raman J, Jeevanandam V. Reversal of impaired myocardial beta‐adrenergic receptor signaling by continuous‐flow left ventricular assist device support. J Heart Lung Transplant. 2010; 29: 603–609. PubMed PMC

Heerdt PM, Holmes JW, Cai B, Barbone A, Madigan JD, Reiken S, Lee DL, Oz MC, Marks AR, Burkhoff D. Chronic unloading by left ventricular assist device reverses contractile dysfunction and alters gene expression in end‐stage heart failure. Circulation. 2000; 102: 2713–2719. PubMed

Terracciano CM, Harding SE, Adamson D, Koban M, Tansley P, Birks EJ, Barton PJ, Yacoub MH. Changes in sarcolemmal Ca entry and sarcoplasmic reticulum Ca content in ventricular myocytes from patients with end‐stage heart failure following myocardial recovery after combined pharmacological and ventricular assist device therapy. Eur Heart J. 2003; 24: 1329–1339. PubMed

Zafeiridis A, Jeevanandam V, Houser SR, Margulies KB. Regression of cellular hypertrophy after left ventricular assist device support. Circulation. 1998; 98: 656–662. PubMed

Hall JL, Grindle S, Han X, Fermin D, Park S, Chen Y, Bache RJ, Mariash A, Guan Z, Ormaza S, Thompson J, Graziano J, de Sam Lazaro SE, Pan S, Simari RD, Miller LW. Genomic profiling of the human heart before and after mechanical support with a ventricular assist device reveals alterations in vascular signaling networks. Physiol Genomics. 2004; 17: 283–291. PubMed

Birks EJ, Hall JL, Barton PJ, Grindle S, Latif N, Hardy JP, Rider JE, Banner NR, Khaghani A, Miller LW, Yacoub MH. Gene profiling changes in cytoskeletal proteins during clinical recovery after left ventricular‐assist device support. Circulation. 2005; 112: I57–I64. PubMed

Lara‐Pezzi E, Terracciano CM, Soppa GK, Smolenski RT, Felkin LE, Yacoub MH, Barton PJ. A gene expression profile of the myocardial response to clenbuterol. J Cardiovasc Transl Res. 2009; 2: 191–197. PubMed

Matkovich SJ, Van Booven DJ, Youker KA, Torre‐Amione G, Diwan A, Eschenbacher WH, Dorn LE, Watson MA, Margulies KB, Dorn GW 2nd. Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support. Circulation. 2009; 119: 1263–1271. PubMed PMC

Francis GS, Anwar F, Bank AJ, Kubo SH, Jessurun J. Apoptosis, Bcl‐2, and proliferating cell nuclear antigen in the failing human heart: observations made after implantation of left ventricular assist device. J Card Fail. 1999; 5: 308–315. PubMed